恩格列净与秋水仙碱用于ST段抬高型心肌梗死直接经皮冠状动脉介入治疗后左心室射血分数降低患者:一项随机双盲三臂平行组对照试验的研究方案
本研究为前瞻性、双盲、平行组、安慰剂对照随机试验,计划纳入105例首次ST段抬高型心肌梗死并接受直接经皮冠状动脉介入治疗及支架植入后左心室射血分数≤40%的患者,按1:1:1随机接受恩格列净10 mg每日、恩格列净10 mg每日联合秋水仙碱0.5 mg每日两次或恩格列净25 mg每日治疗12周。主要结局为随机化至第4周和第12周纽约心脏协会功能分级和高敏C反应蛋白的变化。
要点
- 研究纳入首次ST段抬高型心肌梗死直接PCI后左心室射血分数≤40%的患者105例。
- 三组分别为恩格列净10 mg每日、恩格列净10 mg每日联合秋水仙碱0.5 mg每日两次、恩格列净25 mg每日,疗程12周。
- 主要结局为第4周和第12周纽约心脏协会功能分级及高敏C反应蛋白较基线的变化。
核心结论
- 本研究将是首个评估标准剂量恩格列净联合秋水仙碱以及高剂量恩格列净早期治疗非糖尿病ST段抬高型心肌梗死后左心室射血分数降低患者疗效与安全性的试验。
研究设计与样本
- 前瞻性、双盲、平行组、安慰剂对照随机试验,在Shahid Madani心脏中心(大不里士医科大学附属心血管疾病教学转诊医院)开展。
- 计划纳入105例首次ST段抬高型心肌梗死接受直接经皮冠状动脉介入治疗并植入支架后左心室射血分数≤40%的患者,按1:1:1随机分为三组。
主要发现
- 主要结局为随机化至第4周和第12周纽约心脏协会功能分级和高敏C反应蛋白的变化。
关键数值与推荐
- 恩格列净10 mg每日一次。
- 恩格列净10 mg每日一次联合秋水仙碱0.5 mg每日两次。
- 恩格列净25 mg每日一次。
- 疗程12周。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with acute myocardial infarction are at greater risk for chronic heart failure and mortality. Currently, there is limited evidence supporting the beneficial effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular outcomes in non-diabetic patients with reduced left ventricular ejection fraction following acute myocardial infarction. Furthermore, the clinical effects of the combination of standard-dose sodium-glucose cotransporter-2 inhibitors with colchicine and high-dose sodium-glucose cotransporter-2 inhibitors in this setting have not been evaluated yet. METHODS: A prospective, double-blinded, parallel-group, placebo control randomized trial will be carried out at Shahid Madani Heart Center, the largest teaching referral hospital for cardiovascular diseases, affiliated with Tabriz University of Medical Sciences. A total of 105 patients with reduced left ventricular ejection fraction (≤ 40%) following the first episode of ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention with stent insertion will be randomized 1:1:1 to receive empagliflozin 10 mg daily, a combination of empagliflozin 10 mg daily and colchicine 0.5 mg twice daily, or empagliflozin 25 mg daily for 12 weeks. The primary outcomes are changes in the New York Heart Association functional classification and high-sensitivity C-reactive protein from the randomization through week 4 and week 12. DISCUSSION: The present study will be the first trial to evaluate the efficacy and safety of early treatment with the combination of standard-dose empagliflozin and colchicine as well as high-dose empagliflozin in non-diabetic patients with reduced left ventricular ejection fraction following ST-elevation myocardial infarction. The results of this research will represent a significant step forward in the treatment of patients with acute myocardial infarction. TRIAL REGISTRATION: Clinical trial ID: IRCT20111206008307N39. Registration date: 27 October 2022.
引用
- Khiali S, Taban-Sadeghi M, Sarbakhsh P, et al. Empagliflozin and colchicine in patients with reduced left ventricular ejection fraction following ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: a study protocol for a randomized, double-blinded, three-arm parallel-group, controlled trial. Trials. 2023. PMID: 37803449. doi:10.1186/s13063-023-07682-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。